A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
Clinical trial NCT01283516 · COMPLETED
Trial details
- NCT number
- NCT01283516
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-01-24
- Primary completion
- 2016-05-03
- Enrollment
- 304
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.